BioSpace News Archive

Ortho Clinical Diagnostics (NASDAQ: OCDX), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, has been recognized with a prestigious Gold 2022 Edison Award for its VITROS® Anti-SARS-CoV-2 IgG Quantitative Test COVID-19 testing solutions, helping labs meet demands of the pandemic with reliable mass-scale testing options.

Bioventus Inc., a global leader in innovations for active healing, announced preliminary financial results for the first quarter ended April 2, 2022.

Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation (TRC) to purchase up to 1,000,000 Abbott common shares, representing approximately 0.06% of the company’s outstanding shares.

Neurelis, Inc., announced that it has secured the issuance of United States Patent No. 11,241,414 (the ‘414 Patent) for VALTOCO® (diazepam nasal spray) CIV for acute treatment of episodes of frequent seizure activity in adult and pediatric patients age six and older.

$300M Series D to fund continued growth of Biofourmis’ innovative virtual care solutions.

Medcura, Inc., a commercial-stage medical device company, announced the expansion of its senior management team to include Dr. Kenneth Renkens as its Chief Medical Officer.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive product candidates for pain management, CNS disorders and anti-viral indications, reported preclinical pharmacokinetics (PK) results for VRP324 (MET-CBD), a nose-to-brain delivery platform for CBD for the management of seizures in children and adults

Renovion, Inc., a clinical-stage pharmaceutical company focused on developing treatments for rare, chronic, and serious lung diseases with high unmet needs, announced today that they have received a Study May Proceed Letter from the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical trial to investigate ARINA-1 in non-cystic fibrosis bronchiectasis (NCFBE).

The International Gaucher Alliance and Cerner Corporation announce that the GARDIAN registry is now open for registrations, and the first patient has already enrolled April 25, 2022.

Today, The European Society of Medicine published a study, sponsored by Dr. Ferrer BioPharma of Miami, containing game-changing data on how the world can effectively reduce the effects of COVID-19.